Publications by authors named "Randall M Stevens"

Claim this Profile
S
Stakeholder endorsement advancing the implementation of a patient-reported domain for harms in rheumatology clinical trials: Outcome of the OMERACT Safety Working Group.
Dorthe B Berthelsen, Lee S Simon, John P A Ioannidis, Marieke Voshaar, Pam Richards, Randall M Stevens

Semin Arthritis Rheum· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply.
Randall M Stevens, James N Campbell, Peter D Hanson

Arthritis Rheumatol· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized, Double-Blind, Placebo-Controlled Trial of Intraarticular Trans-Capsaicin for Pain Associated With Osteoarthritis of the Knee.
Randall M Stevens, John Ervin, Jennifer Nezzer, Yeni Nieves, Kimberly Guedes

Arthritis Rheumatol· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
J
JNK inhibition reduces lung remodeling and pulmonary fibrotic systemic markers.
Jos L J van der Velden, Ying Ye, James D Nolin, Sidra M Hoffman, David G Chapman, Randall M Stevens

Clin Transl Med· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial.
Maurizio Cutolo, Gary E Myerson, Roy M Fleischmann, Frédéric Lioté, Federico Díaz-González, Randall M Stevens

J Rheumatol· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3).
Christopher J Edwards, Francisco J Blanco, Jeffrey Crowley, Charles A Birbara, Janusz Jaworski, Randall M Stevens

Ann Rheum Dis· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Current Status, Goals, and Research Agenda for Outcome Measures Development in Behçet Syndrome: Report from OMERACT 2014.
Gulen Hatemi, Yesim Ozguler, Haner Direskeneli, Alfred Mahr, Ahmet Gul, Randall M Stevens

J Rheumatol· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1).
Kim Papp, Kristian Reich, Craig L Leonardi, Leon Kircik, Sergio Chimenti, Randall M Stevens

J Am Acad Dermatol· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Apremilast for Behçet's syndrome--a phase 2, placebo-controlled study.
Gulen Hatemi, Melike Melikoglu, Recep Tunc, Cengiz Korkmaz, Banu Turgut Ozturk, Randall M Stevens

N Engl J Med· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor.
Arthur Kavanaugh, Philip J Mease, Juan J Gomez-Reino, Adewale O Adebajo, Jürgen Wollenhaupt, Randall M Stevens

Ann Rheum Dis· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient-reported Health-related Quality of Life with apremilast for psoriatic arthritis: a phase II, randomized, controlled study.
Vibeke Strand, Georg Schett, Chiachi Hu, Randall M Stevens

J Rheumatol· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improvements in patient-reported outcomes with apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of moderate to severe psoriasis: results from a phase IIb randomized, controlled study.
Vibeke Strand, David Fiorentino, ChiaChi Hu, Robert M Day, Randall M Stevens

Health Qual Life Outcomes· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Apremilast: a novel PDE4 inhibitor in the treatment of autoimmune and inflammatory diseases.
Georg Schett, Victor S Sloan, Randall M Stevens, Peter Schafer

Ther Adv Musculoskelet Dis· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis.
Jonathan C W Edwards, Leszek Szczepanski, Jacek Szechinski, Anna Filipowicz-Sosnowska, Paul Emery, Randall M Stevens

N Engl J Med· June 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intravenous human recombinant tumor necrosis factor receptor p55-Fc IgG1 fusion protein, Ro 45-2081 (lenercept): results of a dose-finding study in rheumatoid arthritis.
Daniel E Furst, Michael Weisman, Harold E Paulus, Kenneth Bulpitt, Michael Weinblatt, Randall M Stevens

J Rheumatol· October 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intravenous human recombinant tumor necrosis factor receptor p55-Fc IgG1 fusion protein Ro 45-2081 (lenercept): a double blind, placebo controlled dose-finding study in rheumatoid arthritis.
Rolf Rau, Oliver Sander, Piet van Riel, Leo van de Putte, Fritz Hasler, Randall M Stevens

J Rheumatol· April 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis